cyrilzakka/clinical-trials huggingface dataset:
Reshaping the Motor Engram - An Online Crowdsourcing Study.

A critical point in learning and memory research is whether memories, once consolidated, remain unchanged or whether they continue to undergo plastic changes and remodeling. While previous research has focused on experimental destabilization during early stages of the memory life cycle, i.e., during encoding or early consolidation, experimental data that provides information about the effect of destabilization interventions on well-consolidated memories is still missing. This is particularly true for the procedural memory domain, such as learning a sensorimotor skill. This project is designed to characterize the effect of a single behavioral interference intervention on a previously consolidated sensorimotor skill in a large sample of healthy volunteers recruited through an online crowdsourcing platform. In a longitudinal design, participants will perform an implicit sequence learning task over five consecutive sessions, followed by an interference intervention in session six and a follow-up evaluation of the stability of the learned skill in session seven. The experimental design includes two levels of sequential information (spatial and temporal), which allows the testing of the specificity of the interference intervention. Behavioral performance throughout the experimental sessions is acquired via the manual input on the participants' computer keyboards and used to extract the learning rate and the interference effect (primary outcome).


Eligibility Criteria:
Inclusion Criteria:

* registered Amazon Mechanical Turk users (called 'workers')
* with \>95% approval rate on all previous Amazon Mechanical Turk assignments
* location in North America or Europe
* ≥18 years of age
* not having participated in this experiment before

Exclusion Criteria:

• prior participation in this experiment
Injection of Hormone to Enhance Implantation in Embryo Transfer After IVF

The endometrium is deprived of signals form the embryo in IVF conditions. Studies suggest that placing HCG into the uterus prior to embryo transfer can enhance implantation.

The study is in pilot phase, uncontrolled. The risks appear to be minimal and there are conflicting new reports being announced.

A small amount of fluid with HCG is injected into the uterus. HCG is a potent signal to the uterus for preparation for implantation.

This is not a funded study. Three published studies suggest the approach is valid; one refutes the concept.

Eligibility Criteria:
Inclusion Criteria:

- infertility patients undergoing IVF with good expectation of two embryos day 3 or day 5. must speak and read English. Includes donor eggs.

Exclusion Criteria:abnormal uterus

-
Computer Aided Respiratory Therapy Based on Audio and Spirometry Signals

The purpose of the study is to collect data: audio in the form of respiratory sounds and instructions from the therapist, spirometry data during the execution of the therapy, physiological parameters, and patient information. With the help of this data, algorithms will be developed for the automatic detection, localization, and classification of respiratory sounds, linked to the respiratory cycle using spirometric signals.

The study is an interventional study. Patients receive their standard respiratory physiotherapy, but in the mean time they are monitored with a stethoscope, spirometer and a wearable to measure physio-logical parameters.

It has been chosen to intervene as little as possible in the therapy to measure the respiratory sounds and breathing of the patient as accurately as possible. By recording therapy sessions with 15 patients, we expect to register several hundred events of respiratory sounds. This provides a good foundation for training an algorithm to detect and classify respiratory sounds.

Eligibility Criteria:
Inclusion Criteria:

* The patient has a chronic or acute respiratory condition and may need oxygen therapy
* The patient is minimally 12 years old

Exclusion Criteria:

* The patient is cognitively impaired.
* The patient has an undrained pneumothorax.
* The patient is experiencing an acute pulmonary hemorrhage.
* The patient is having an asthma exacerbation.
* The patient has an infection with Burkholderia cepatia.
* The patient is in isolation due to the risk of infection.
CANA/Met in Non-diabetic Women With PCOS

Polycystic ovary syndrome (PCOS), which is associated with hyperinsulinaemia, hyperandrogenaemia, impaired glucose metabolism and aberrant adipokines production from the adipose tissue, is a heterogeneous reproductive and endocrine disorder.Currently, metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS. SGLT-2 inhibitor, a novel glucose-lowering medication, have been shown to have positive effects on reducing body weight, blood pressure and cardiovascular events in individuals with diabetes mellitus. However, evidences related to its management in non-diabetic PCOS women are limited. Hence, we want to give canangliflozin combined with metformin to women with PCOS to see its effect on insulin resistance.


Eligibility Criteria:
Inclusion Criteria:

1. Female aged 18- 45 years old;
2. Diagnosed criteria meet the Rotterdam criteria (2003);
3. Insulin Resistance

Exclusion Criteria:

1. Women who are pregnant or have a pregnancy plan within six months;
2. Confirmed diagnosis of diabetes.
3. Congenital adrenocortical hyperplasia;
4. Hyperprolactinemia;
5. Hyperthyroidism or hypothyroidism;
6. Combined with liver or kidney diseases;
7. Abnormal liver function (≥ 3 times of the upper limit of normal range);
8. Abnormal renal function (GFR\<60ml/min/1.73m2);
9. Adrenal or ovarian tumors secreting androgens;
10. Used metformin, glucagon-like peptide-1 receptor agonists, pioglitazone and contraceptives in the last 3 months.
Promoting Medication Adherence Among Older Adults With Hypertension

Over 70% of US adults 65 or older are diagnosed with hypertension, the leading cause of cardiovascular disease and premature deaths in the world. Despite availability of effective drugs to control blood pressure, uncontrolled blood pressure and low adherence to antihypertensive drugs persist as major public health and clinical challenges. On average, 50% of adults adhere to chronic disease medications and lower levels of adherence are associated with worse blood pressure control and adverse outcomes. Many barriers to adherence are well known and have been targeted in interventions to improve medication adherence. As of yet, no single intervention has emerged as superior or even particularly effective in improving adherence. The investigators have recently identified unconscious, self-protective 'hidden motives' that contribute to nonadherence to chronic disease medications. There is a critical need to expand on this insight to test the potential for targeting individuals' 'hidden motives' for low adherence using an innovative learning process called Immunity-to-Change.

As a critical step in testing this intervention to target these 'hidden motives', the investigators will undertake a pilot study to assess the feasibility and acceptability of the Overcoming Immunity-to-Change intervention and determine effect sizes of the intervention on adherence, blood pressure (BP) control, and quality of life (QOL). The investigators will test the Immunity-to-Change intervention in a sample of nonadherent older adults with hypertension (n=18). Another sample of nonadherent older adults with hypertension will be monitored for comparison (n=18).


Eligibility Criteria:
Inclusion Criteria:

* Men and women ages 55 and older, with the goal of a sex- and race-balanced sample
* Diagnosis of essential hypertension
* Uncontrolled hypertension
* Current treatment with antihypertensive medication
* Low antihypertensive pharmacy refill
* English speaking
* Telephone access
* Ability to read print on a computer screen and use the computer keyboard
* Written consent to participate and HIPAA authorization
* Written acceptance of study contract
* Approval of health care provider

Exclusion Criteria:

* Cognitive impairment
* Enrollment in another clinical trial
Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)

Phase II study of rituximab plus MG4101 in patients with relapsed or refractory indolent CD20-positive non-Hodgkin lymphoma (NHL) Investigator-Initiated Trials

Multi-center trial, Phase II, non-randomized, open-label, single-arm study with combined therapy of rituximab plus MG4101 in patients with indolent CD20-positive NHLs who has relapsed or refractory to prior chemotherapy or chemo-radiotherapy.

Eligibility Criteria:
Inclusion Criteria:

1. Histologically confirmed indolent CD20-positive NHLs (iNHLs; follicular lymphoma grade 1-3a, marginal zone B-cell lymphoma, small lymphocytic lymphoma, Waldenstrom macroglobulinemia)
2. CD20-positive iNHL patients who relapsed or progressed
3. ≥ 19 years
4. ECOG PS 0-2
5. At least one bidimensionally measurable disease (or presence of IgM paraproteinemia ≥ 2 x ULN for Waldenstrom macroglobulinemia)
6. Adequate hematologic, renal, and hepatic functions
7. Appropriate methods of contraception during the study
8. Written informed consent

Exclusion Criteria:

1. Not all of the above inclusion criteria are met.
2. Prior chemotherapy within 4 weeks or radiotherapy within 6 weeks
3. Corticosteroids \> 10mg/day during last 28 days
4. Evidence of CNS involvement by lymphomas
5. Active HBV/HCV infections, known HIV infection
6. Prior diagnosis of cancers within 5 years
7. Serious concurrent cardiovascular disease
8. Patients who are pregnant or lactating
Physician-Patient Communication and Expectations Regarding Ovarian Cancer Prognosis

The primary objective is to administer a cross-sectional survey to directly compare the differences patients and physicians hold regarding ovarian cancer prognosis and survival, complications arising from treatment, and counseling on advance directives, living wills, palliative care, and hospice services. Overall, the project will pinpoint opportunities for better patient physician communication regarding prognosis and end-of-life care and allow for more informed and tailored decision-making.


Eligibility Criteria:
Inclusion Criteria:

* women over 18 years old with biopsy-confirmed malignancy
* being actively treated or are in surveillance for epithelial ovarian cancer
* have an existing therapeutic relationship with a provider who is participating in the study.

Exclusion Criteria:

* patients enrolled in palliative or hospice care programs, patients with a second primary malignancy within the last five years (excluding non-melanoma skin cancer)
* patients who are illiterate or non-English speaking, and patients without decision-making capacity.
* There are no exclusion criteria based on age, gender, economic status or race/ethnicity
BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer

The primary objective of this study is to evaluate PFS rate at 9 months of BIBF 1120 in combination with mFolfox6 compared with mFolfox6 combined to bevacizumab in first line patients with metastatic colorectal cancer.


Eligibility Criteria:
Inclusion criteria:

1. Age \>= 18 years
2. Histologically proven colorectal adenocarcinoma
3. No previous oxaliplatin based chemotherapy is allowed unless disease free survival after the end of chemotherapy \> = 12 months
4. No previous therapy with VEGFR or EGFR inhibitors
5. No prior systemic therapy for metastatic CRC
6. No previous adjuvant therapy with fluoropyrimidines is allowed unless disease free survival after the end of chemotherapy \> 6 months
7. ECOG performance status \< = 2
8. Adequate hepatic, renal and bone marrow functions:
9. No uncontrolled hypertension
10. Signed and dated written informed consent prior to admission to the study

Exclusion criteria:

1. Treatment with any investigational drug within 28 days of trial onset.
2. History of other malignancies in the last 5 years, in particular those that could affect compliance with the protocol or interpretation of results.
3. Serious concomitant disease, especially those affecting compliance with trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug,
4. Major injuries and/or surgery or bone fracture within 4 weeks of trial inclusion, or planned surgical procedures during the trial period.
5. Significant cardiovascular diseases
6. History of severe haemorrhagic or thromboembolic event in the past 12 months. Known inherited predisposition to bleeding or to thrombosis.
7. Patient with brain metastases that are symptomatic and/or require therapy.
8. Pregnancy or breast-feeding.
Intrarenal Pressure Monitoring Via Flexible and Navigable Suction Ureteral Access Sheath in Retrograde Intrarenal Surgery

This study evaluates the use of a novel intrarenal pressure (IRP)-monitoring flexible and navigable suction ureteral access sheath (FANS) in retrograde intrarenal surgery (RIRS) for renal stones. The prospective clinical trial compares its efficacy and safety against conventional FANS in 100 patients. The primary outcomes include IRP monitoring accuracy, operative time, stone-free rate (SFR), and complication rates, with the aim of improving stone retrieval efficiency and procedural safety in RIRS. This trial seeks to validate the innovative device's role in expanding RIRS indications, especially for large renal stones.


Eligibility Criteria:
Inclusion Criteria:

1. Adult patients (18-75 years old) diagnosed with renal stones (size ≤4 cm) and suitable for retrograde intrarenal surgery (RIRS).
2. Willing to provide informed consent.
3. No significant renal, cardiac, or systemic diseases that may interfere with the surgical procedure or the study.
4. Preoperative intravenous pyelography (IVP) showing no significant ureteral stricture.

Exclusion Criteria:

1. Patients with active urinary tract infections (UTIs) or fever at the time of surgery.
2. Pregnancy or breastfeeding women.
3. Patients with a history of severe renal disease (e.g., chronic kidney disease stage 3 or higher).
4. History of prior ureteral or renal surgery that may affect the anatomy.
5. Patients with uncontrolled comorbidities such as uncontrolled diabetes, hypertension, or cardiovascular disease.
6. Patients who are unwilling or unable to comply with the study protocol.
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients

This study will determine the relative efficacy and safety of up to 100 days Valcyte prophylaxis relative to up to 200 days Valcyte prophylaxis when given for the prevention of CMV disease in high-risk (D+/R-) kidney allograft recipients. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.


Eligibility Criteria:
Inclusion Criteria:

* ≥ 16 years of age
* CMV seronegative recipient of primary or secondary renal allograft from a living or cadaveric seropositive donor
* Adequate hematological and renal function
* Patients and partners must agree to maintain effective birth control for 90 days following cessation of study medication

Exclusion Criteria:

* CMV disease, or receipt of anti-CMV therapy within 30 days prior to screening
* Multi-organ transplant recipient
* Hepatitis B, hepatitis C or HIV positive
* Women who are pregnant or lactating
Prognositc Factors in COVID-19 Patients Complicated With Hypertension

There are currently no clinical studies reporting clinical characteristics difference between the hypertension patients with and without ACEI treatment when suffered with novel coronavirus infection in China.

At present, the outbreak of the new coronavirus (2019-nCoV) infection in Wuhan and Hubei provinces has attracted great attention from the medical community across the country. Both 2019-nCoV and SARS viruses are coronaviruses, and they have a large homology.

Published laboratory studies have suggested that SARS virus infection and its lung injury are related to angiotensin-converting enzyme 2 (ACE2) in lung tissue. And ACE and ACE2 in the renin-angiotensin system (RAS) are vital central links to maintain hemodynamic stability and normal heart and kidney function in vivo.

A large amount of evidence-based medical evidence shows that ACE inhibitors are the basic therapeutic drugs for maintaining hypertension, reducing the risk of cardiovascular, cerebrovascular, and renal adverse events, improving quality of life, and prolonging life in patients with hypertension. Recent experimental studies suggest that treatment with ACE inhibitors can significantly reduce pulmonary inflammation and cytokine release caused by coronavirus infection.

Eligibility Criteria:
Inclusion Criteria:

* Adult aged \>=18years old;
* Diagnosed with 2019-nCoV. Diagnostic criteria including: Laboratory (RT-PCR) confirmed 2019-nCoV infection; CT of the lung conformed to the manifestation of viral pneumonia.
* Diagnosed with primary hypertension.
* Criteria for severe or critical ill conditions: Respiratory rate \>=30/min; or Rest SPO2\<=93%; or PaO2/FiO2\<=300mmHg.

Exclusion Criteria:

* Near-death state (expected survival time less than 24 hours);
* Malignant tumor;
* Pregnancy or puerperium women;
* ACEI contraindication
* Patients who refused to participant.
Comparison of The Clinical Effects Between Different Physical Therapy Tools in Patellofemoral Pain Patients

Objectives:The purpose of this study was to investigate the different effects among the quadriceps strength training, taping, and stretching exercise of iliotibial band in patients with patellofemoral pain syndrome by randomized control trial study.

Method:An observer blind, prospective, factorial design randomized controlled trail. 90 young adults with patellofemoral pain syndrome were randomly allocated into one of three treatment groups: (1) Quadriceps strength training, (2) taping, and (3) stretch. Each group received treatment for 8 weeks.

Hypothesis:Patients in quadriceps strength training group may get most outcomes in three groups

Introduction:Patellofemoral pain syndrome ( PFPS ) is a common knee disorder. Factors that cause patellofemoral pain include: over use, soft tissue imbalance, and malalignment of lower extremity. Patients with patellofemoral pain, caused by soft tissue imbalance was thought to be favorite to receive physical therapies. Clinically, physical therapies for patients with PFPS are including: Quadriceps strength training, taping, and stretching exercise. The aforementioned treatment tools showed different effect mechanism. However, there were few clinical studies to compare the clinical effects among the aforementioned three treatment tools. The purpose of this study was to investigate the different effects among the quadriceps strength training, taping, and stretching exercise of iliotibial band in patients with patellofemoral pain syndrome by randomized control trial study.

Methods:An observer blind, prospective, factorial design randomized controlled trail. 90 young adults with patellofemoral pain syndrome were randomly allocated into one of three treatment groups: (1) Quadriceps strength training, (2) taping, and (3) stretch. Each group received treatment for 8 weeks.

Outcome measures were including visual analog scales for worst pain, active-active joint reposition error test, the Chinese version of the Western Ontario and McMaster Universities Osteoarthritis Index, and one repetition maximum recorded at baseline and after the interventions for 8 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Anterior or retropatellar knee pain present during at least two of the following: ascending/descending stairs, hopping, running, squatting, kneeling, and prolong sitting
* Insidious onset of symptom unrelated to a traumatic incident
* Pain on palpation of peripatella
* VAS\>3
* Age \<50 years old
* Symptoms sustained for more than 1 month

Exclusion Criteria:

* Over activity: athlete, infatry
* Patients with meniscal lesion, ligamentous instability, patellar tendon pathology, radiation pain from spine, referred pain
* Neurological disease involved
Study Using the ShiraTronics Migraine Therapy System

The purpose of this pilot study is to assess the preliminary safety and efficacy of the ShiraTronics Migraine Therapy System in prophylactic treatment of patients with refractory chronic migraine.


Eligibility Criteria:
Inclusion Criteria:

1. Participants who are 22 years of age or older.
2. History of migraine ≥ 12 months.
3. Participants experiencing between 15 to 26 headache days per month, with at least 8 headache days (per month) with migraine phenotype presentation.
4. Inadequate response to, unwilling, or contraindicated to Onabotulinumtoxin A and CGRP monoclonal antibodies therapy.
5. Stable use of migraine medication.

Exclusion Criteria:

1. Post-traumatic headache.
2. Medication overuse headache.
3. New daily persistent headache.
4. Report experiencing unremitting, continuous headaches with no relief.
5. Previously implanted neurostimulator to treat headache.
6. History of cervical radiofrequency ablation or had any other intervention/device for migraine.
Magnetic Anastomosis Device Relief of Malignant Gastric Outlet Obstruction

The purpose of this study is to determine if the Cook Magnetic Anastomosis Device can be used to safely and successfully create a patent gastrojejunal anastomosis in subjects requiring treatment of gastric outlet obstruction caused by malignancy.

Surgical treatments for malignant gastric outlet obstructions carry substantial risks and are associated with postoperative morbidity. External compression from advancing tumor or tissue growth through the stent can cause stenosis or re-obstruction. In these patients, the creation of a patent fistula that allows gastric emptying may significantly improve palliation. Minimally invasive techniques that carry no greater risks than enteral stenting may provide a viable palliative treatment. The primary objectives are safety, and successful creation of a gastro-jejunal anastomosis. Secondary objectives are successful resumption or improvement in the ability to tolerate PO feeding, rate of stent migration, and duration of stent and anastomosis patency.

Eligibility Criteria:
Inclusion Criteria:

* Patients with unresectable malignancy with, or at risk of developing gastric outlet obstruction with GOOSS ≤ 2
* Karnofsky Performance Score ≥ 60

Exclusion Criteria:

* Patient is unable to understand and execute informed consent
* Age below 18 years
* Patients with any prior gastrointestinal surgery that significantly alters gastrojejunal anatomy
* Implanted cardiac pacemaker, defibrillator or ventricular assist device
* Requirement for chronic anticoagulation, or with uncorrectable coagulopathy
* Patients receiving chronic steroids or other drugs that may impair wound healing or formation of an intact anastomosis
* Simultaneously participating in another investigational drug or device
* Patients with suspicion of, or documented multiple small bowel strictures